It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Investing in stocks requires a strategic approach. Learn about the best strategies to enhance your success and navigate the stock market effectively.
22,240 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A wave of mid contract terminations by hospital systems is reshaping Medicare Advantage. Investors and patients confr...
A practical look at Farmland Partners (FPI) earnings and what they mean for investors. We break down the numbers, tre...
NCS Multistage's Q4 2025 earnings call offers insight into margins, backlog, and growth drivers. This guide translate...
Tejon Ranch (TRC) 2025 is shaping up as a pivotal year for investors tracking large-scale land development and partne...
NVIDIA stakes its AI dominance on data center hardware while Palantir expands software driven growth, setting up a hi...
A famous actor’s outspoken take on government can feel distant from your budget. This article explains how public dis...
As tech’s power demand surges, data centers are becoming a bigger profit driver for utilities, prompting fresh debate...
A single-session drop in the 3X leveraged FNGU ETN trimmed a $10,000 bet to $8,392, illustrating how tech leverage ca...
Two bold bets sit at the frontier of transport and connectivity: a space-based mobile network and a next-gen urban ai...
A risk-off mood is weighing on major cryptos as ETF redemptions surge. This guide breaks down the forces at work and ...
Both XLP (State Street) and IYK (iShares) offer refuge in volatile markets. This guide breaks down costs, risk, and i...